WC
STSA

Wexford Capital’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Wexford Capital’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8,365
Closed -$39K – 387
2020
Q4 		$39K Buy
+8,365
New +$36.1K 0.01% 269

Other funds holding STSA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wexford Capital's STSA Position: Q1 2021 in Review

Wexford Capital sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q1 2021, closing a stake of 8,365 shares — an estimated $39K sold.

Wexford Capital first reported a position in STSA in Q4 2020 and held it in 1 quarter. The position peaked at $39K in Q4 2020. 61 funds tracked by Wall St. Rank hold STSA as of Q1 2021.

  • Wexford Capital reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Wexford Capital sold 8,365 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q1 2021, an estimated $39K.
  • Wexford Capital first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Wexford Capital's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $39K in Q4 2020.
  • 61 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.